Clinical Trial

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2024 (before its estimated December 11, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center real-world study, in which patients who meet the inclusion criteria will receive treatment with Pyrotinib + Trastuzumab + Taxanes. Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events (AEs), after which Capecitabine will be used for rhythmic chemotherapy combined with Pyrotinib + Trastuzumab. The aim is to explore the efficacy and safety of Pyrotinib, Trastuzumab, and Taxanes in treating Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-11.
Trial Details
NCT Number NCT06217185
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions HER2-positive Breast Cancer, Advanced Breast Cancer
Enrollment 100 participants
Start Date 2024-01-02
Primary Completion 2025-12-11 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-28